Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Solasta Bio | 2024 | Series A | Undisclosed | Glasgow |
| CatalYm | 2024 | Series D | Undisclosed | Planegg |
| RQ Bio | 2026 | Series A | Undisclosed | London |
| Dyne Therapeutics | 2026 | Post-IPO Debt | Undisclosed | Cambridge |
| AIRNA | 2025 | Series B | Undisclosed | Cambridge |
| Engrail Therapeutics | 2024 | Series B | Undisclosed | San Diego |
| Mestag Therapeutics | 2026 | Series Unknown | $40.0M | Cambridge |
| Precirix | 2022 | Series B | Undisclosed | Brussels |
| Tropic Biosciences | 2026 | Series C | $105.0M | London |
| PACT | 2025 | Series A | $21.1M | Cambridge |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | Solasta Bio | Series A | Undisclosed | Glasgow, United Kingdom |
| 2 | CatalYm | Series D | Undisclosed | Planegg, Germany |
| 3 | RQ Bio | Series A | Undisclosed | London, United Kingdom |
| 4 | Dyne Therapeutics | Post-IPO Debt | Undisclosed | Cambridge, United States |
| 5 | AIRNA | Series B | Undisclosed | Cambridge, United States |
| 6 | Engrail Therapeutics | Series B | Undisclosed | San Diego, United States |
| 7 | Mestag Therapeutics | Series Unknown | $40.0M | Cambridge, United Kingdom |
| 8 | Precirix | Series B | Undisclosed | Brussels, Belgium |
| 9 | Tropic Biosciences | Series C | $105.0M | London, United Kingdom |
| 10 | PACT | Series A | $21.1M | Cambridge, United Kingdom |
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.
RQ Bio is a biotechnology company that develops medicine based on potent broad-spectrum mAbs to provide immunity to viral infections.
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
AIRNA develops RNA editing technologies to create medicines for various diseases.
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology.
Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.
Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.
PACT designs Elegant materials produced in tune with the planet earth.
Elevara is a clinical-stage firm working on innovative therapies to treat rheumatoid arthritis and other chronic inflammatory disorders.
Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.
Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.
Eeden converts end-of-life textiles into resources for new textile production.
Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.
Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington's disease.
NOVAMEAT develops cutting-edge technological solutions to feed the planet's growing population with plant-based foods.
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.
Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
A UK-based developer of drugs to treat respiratory diseases
Forbion Capital Partners has invested in 36 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Forbion Capital Partners's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 22 different industry categories.
Among tracked funding rounds, Expedition Therapeutics received $165.0M in a Series A round. Forbion Capital Partners's total known invested capital is $6.2B.
Forbion Capital Partners's average investment size is $87.8M across its portfolio of 36 companies.
Recent Forbion Capital Partners portfolio additions include Solasta Bio, CatalYm, RQ Bio, Dyne Therapeutics, AIRNA. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors